Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Caroline F. Pratz
The Effect of Therapeutic Anticoagulation on Overall Survival in Men Receiving First-Line Docetaxel Chemotherapy for Metastatic Castration-Resistant Prostate Cancer
Clinical Genitourinary Cancer
Oncology
Urology
Related publications
Cabazitaxel in the Management of Metastatic Castration-Resistant Prostate Cancer Progressing After Docetaxel-Based Chemotherapy
European Oncology and Haematology
Oncology
Hematology
Treatment Sequences, Patient Characteristics, and Overall Survival of Patients With Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer in the Community Setting
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
LINE-1 as a Therapeutic Target for Castration-Resistant Prostate Cancer
Frontiers in Bioscience - Landmark
Immunology
Molecular Biology
Biochemistry
Microbiology
Medicine
Genetics
Outcome of Combination Chemotherapy With Docetaxel, Estramustine Phosphate, and Carboplatin After Docetaxel and Prednisolone Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Journal of Cancer Therapy
Predictive Factors of Response and Overall Survival in Patients With Castration-Resistant Metastatic Prostate Cancer Undergoing177Lu-Psma Therapy
Journal of Nuclear Medicine
Medicine
Nuclear Medicine
Radiology
Imaging
Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-Resistant Prostate Cancer After Chemotherapy
Klinicka Onkologie
Oncology
Pcn336 - Treatment of Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With Docetaxel in Portugal
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer
JAMA Oncology
Cancer Research
Oncology
Phase II Randomized Study of Figitumumab Plus Docetaxel and Docetaxel Alone With Crossover for Metastatic Castration-Resistant Prostate Cancer
Clinical Cancer Research
Cancer Research
Oncology
